open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2016-07-20
Get Citation

Standards of diagnostic and new trends in treatment in patients with acute myeloid leukemia

Dagmara Szmajda1, Ewa Balcerczak, Adrian Krygier1
DOI: 10.1016/j.achaem.2017.07.009
·
Acta Haematol Pol 2017;48(4):291-299.
Affiliations
  1. Pracownia Diagnostyki Molekularnej i Farmakogenomiki, Zakład Biochemii Farmaceutycznej i Diagnostyki Molekularnej, Międzywydziałowa Katedra Diagnostyki Laboratoryjnej i Molekularnej, Uniwersytet Medyczny w Łodzi, Kierownik Katedry prof. dr hab. Ewa Balcerczak, Polska

open access

Vol 48, No 4 (2017)
Prace poglądowe / Reviews
Published online: 2017-10-01
Submitted: 2016-07-20

Abstract

Acute myeloid leukemia (AML) is the most common cancer of white blood cells in adults. Men over 65 years old are more prone to develop this disease. Symptoms that lead patients to visit the doctor are: high fever, bone pain, weakness and signs of infection. The etiology of AML is not yet fully understood. The predisposing factors for acute myeloid leukemia may include environmental and genetic factors. If left untreated, it can lead to death within a few weeks. Therefore, it is important to quickly identify the disease and to implement appropriate treatment, which will allow to increase the percentage of survival among patients. The basis of AML diagnosis is the presence of more than 20% of blasts in blood or bone marrow smears. The choice of AML treatment depends on prognostic factors: patients’ age and sex and cytogenetic-molecular risk. The treatment regimen for AML is outdated and remains almost unchanged for over 30 years. Understanding the molecular basis of this disease development and pathomechanism allows to search for new effective treatments, often based on targeted therapies. This article presents contemporary standards of AML diagnosis and the latest trends in its treatment.

Abstract

Acute myeloid leukemia (AML) is the most common cancer of white blood cells in adults. Men over 65 years old are more prone to develop this disease. Symptoms that lead patients to visit the doctor are: high fever, bone pain, weakness and signs of infection. The etiology of AML is not yet fully understood. The predisposing factors for acute myeloid leukemia may include environmental and genetic factors. If left untreated, it can lead to death within a few weeks. Therefore, it is important to quickly identify the disease and to implement appropriate treatment, which will allow to increase the percentage of survival among patients. The basis of AML diagnosis is the presence of more than 20% of blasts in blood or bone marrow smears. The choice of AML treatment depends on prognostic factors: patients’ age and sex and cytogenetic-molecular risk. The treatment regimen for AML is outdated and remains almost unchanged for over 30 years. Understanding the molecular basis of this disease development and pathomechanism allows to search for new effective treatments, often based on targeted therapies. This article presents contemporary standards of AML diagnosis and the latest trends in its treatment.

Get Citation

Keywords

Acute myleoid leukemia; Targeted therapy; Diagnostic standards; Clinical trials; New drugs

About this article
Title

Standards of diagnostic and new trends in treatment in patients with acute myeloid leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 4 (2017)

Pages

291-299

Published online

2017-10-01

DOI

10.1016/j.achaem.2017.07.009

Bibliographic record

Acta Haematol Pol 2017;48(4):291-299.

Keywords

Acute myleoid leukemia
Targeted therapy
Diagnostic standards
Clinical trials
New drugs

Authors

Dagmara Szmajda
Ewa Balcerczak
Adrian Krygier

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl